Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Joel Marrs

Concepts (180)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
7
2022
423
1.520
Why?
Antihypertensive Agents
5
2021
489
1.510
Why?
Pharmacists
8
2023
263
1.380
Why?
Hypertension
7
2021
1245
1.350
Why?
Aspirin
3
2015
383
1.120
Why?
Text Messaging
3
2025
149
1.090
Why?
Platelet Aggregation Inhibitors
3
2015
454
1.070
Why?
Education, Pharmacy
6
2023
137
0.940
Why?
Cardiovascular Diseases
9
2025
2028
0.930
Why?
Hypolipidemic Agents
4
2025
93
0.930
Why?
Atrial Fibrillation
2
2019
383
0.830
Why?
Diabetes Mellitus, Type 2
7
2017
2440
0.820
Why?
Anticoagulants
2
2019
627
0.820
Why?
Thiophenes
2
2015
119
0.740
Why?
Stroke
4
2019
1119
0.730
Why?
Dyslipidemias
4
2025
177
0.720
Why?
Allylamine
2
2012
8
0.720
Why?
Internship, Nonmedical
2
2010
16
0.610
Why?
Medication Reconciliation
1
2018
29
0.580
Why?
Kidney Failure, Chronic
2
2011
560
0.480
Why?
Pharmaceutical Services
2
2020
84
0.480
Why?
Heart Failure, Diastolic
1
2015
21
0.480
Why?
Cholesterol, LDL
5
2019
361
0.470
Why?
Ticlopidine
1
2015
55
0.470
Why?
Practice Guidelines as Topic
5
2019
1537
0.470
Why?
Drug-Eluting Stents
1
2015
65
0.470
Why?
Thromboembolism
1
2015
106
0.460
Why?
Medically Underserved Area
1
2015
82
0.460
Why?
Hypoglycemic Agents
2
2012
1218
0.420
Why?
Piperazines
1
2015
334
0.400
Why?
Guideline Adherence
1
2016
534
0.400
Why?
Blood Pressure
3
2016
1753
0.400
Why?
Reminder Systems
2
2025
174
0.390
Why?
Urban Population
1
2015
439
0.390
Why?
Patient Discharge
2
2018
866
0.390
Why?
Glucosides
1
2012
37
0.380
Why?
Cardiovascular Agents
2
2025
156
0.370
Why?
Thrombosis
1
2015
337
0.370
Why?
Venous Thromboembolism
1
2015
277
0.370
Why?
Humans
45
2025
130305
0.370
Why?
Anticholesteremic Agents
2
2012
146
0.360
Why?
Spironolactone
1
2010
28
0.350
Why?
Mineralocorticoid Receptor Antagonists
1
2010
46
0.350
Why?
Administration, Oral
3
2019
788
0.320
Why?
Preceptorship
1
2010
73
0.320
Why?
Professional Role
3
2020
160
0.310
Why?
Students, Pharmacy
1
2010
114
0.300
Why?
Medication Therapy Management
2
2020
71
0.300
Why?
Schools, Pharmacy
3
2021
56
0.290
Why?
Drug Therapy, Combination
4
2016
1028
0.280
Why?
Benzodiazepines
1
2008
133
0.280
Why?
Angiotensin-Converting Enzyme Inhibitors
3
2021
207
0.280
Why?
Hypnotics and Sedatives
1
2008
159
0.270
Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2007
45
0.270
Why?
Angiotensin Receptor Antagonists
2
2021
94
0.270
Why?
Medication Adherence
3
2025
577
0.270
Why?
Certification
3
2013
95
0.260
Why?
Renal Dialysis
1
2010
425
0.260
Why?
Insurance Coverage
1
2008
223
0.260
Why?
Family Practice
2
2010
453
0.260
Why?
Hospitalization
2
2015
2094
0.250
Why?
Sleep Initiation and Maintenance Disorders
1
2008
150
0.250
Why?
Aged
11
2025
22282
0.250
Why?
Heart Failure
1
2018
2164
0.230
Why?
Poverty
1
2008
496
0.230
Why?
Faculty
2
2017
135
0.230
Why?
Endocrinology
1
2025
74
0.220
Why?
Ambulatory Care
1
2007
511
0.210
Why?
Social Identification
1
2023
59
0.200
Why?
Specialization
3
2013
147
0.200
Why?
Middle Aged
11
2025
31322
0.200
Why?
Pharmacy
1
2021
32
0.180
Why?
Colesevelam Hydrochloride
2
2012
8
0.180
Why?
Cell Phone
1
2021
70
0.180
Why?
Pharmacy Service, Hospital
2
2013
96
0.170
Why?
Secondary Prevention
3
2016
238
0.170
Why?
Brain Ischemia
2
2013
309
0.160
Why?
Female
13
2025
68842
0.160
Why?
Diabetes Mellitus
2
2020
1005
0.160
Why?
Retrospective Studies
6
2021
14675
0.150
Why?
Software
1
2023
616
0.150
Why?
Societies, Pharmaceutical
3
2021
25
0.150
Why?
Age Factors
2
2016
3153
0.150
Why?
Heart Valve Diseases
1
2019
170
0.140
Why?
Colorado
2
2023
4471
0.140
Why?
Blood Glucose
3
2012
2100
0.140
Why?
Male
11
2025
63748
0.140
Why?
4-Hydroxycoumarins
1
2016
4
0.130
Why?
Dissociative Disorders
1
2016
21
0.130
Why?
Vitamin K
1
2016
42
0.130
Why?
Community Participation
1
2017
126
0.130
Why?
Cholesterol
3
2019
407
0.130
Why?
Clinical Trials as Topic
2
2012
1015
0.130
Why?
Risk Factors
5
2019
9865
0.130
Why?
Aged, 80 and over
4
2015
7128
0.130
Why?
Primary Prevention
2
2014
193
0.120
Why?
Patient Transfer
1
2018
166
0.120
Why?
Adult
8
2025
35711
0.120
Why?
Blood Coagulation Disorders
1
2016
164
0.120
Why?
Guidelines as Topic
1
2016
262
0.110
Why?
Telemedicine
1
2022
791
0.110
Why?
Diuretics
2
2011
74
0.110
Why?
United States
8
2025
14110
0.110
Why?
Suicide, Attempted
1
2016
357
0.100
Why?
Treatment Outcome
2
2019
10341
0.100
Why?
Emotional Intelligence
2
2023
8
0.100
Why?
Follow-Up Studies
3
2016
4961
0.100
Why?
Acute Disease
1
2015
981
0.100
Why?
Benzhydryl Compounds
1
2012
65
0.090
Why?
Data Collection
1
2014
654
0.090
Why?
Health Promotion
1
2017
717
0.090
Why?
Hyperlipidemias
1
2012
126
0.090
Why?
Atherosclerosis
1
2015
407
0.090
Why?
Continuity of Patient Care
1
2013
280
0.090
Why?
Sex Factors
1
2016
1965
0.090
Why?
Cross-Sectional Studies
1
2021
5083
0.090
Why?
Universities
1
2013
406
0.080
Why?
Drug Resistance
1
2010
168
0.080
Why?
Interinstitutional Relations
1
2010
56
0.080
Why?
Drug Monitoring
1
2010
194
0.080
Why?
Myocardial Infarction
1
2016
1036
0.080
Why?
Pregnancy
1
2021
6301
0.080
Why?
Coronary Artery Disease
1
2015
697
0.080
Why?
Advisory Committees
2
2021
231
0.070
Why?
Patient-Centered Care
1
2013
506
0.070
Why?
Receptors, GABA-A
1
2008
96
0.070
Why?
Dipeptidyl Peptidase 4
1
2007
13
0.070
Why?
Adamantane
1
2007
16
0.070
Why?
Emotions
2
2023
537
0.070
Why?
Pyrrolidines
1
2007
65
0.070
Why?
Practice Patterns, Physicians'
1
2015
1294
0.070
Why?
Eicosapentaenoic Acid
1
2006
36
0.070
Why?
Nitriles
1
2007
162
0.070
Why?
Hypertriglyceridemia
1
2006
39
0.070
Why?
Exercise
1
2017
1941
0.060
Why?
Docosahexaenoic Acids
1
2006
83
0.060
Why?
Aging
1
2016
1785
0.060
Why?
Young Adult
4
2015
12404
0.060
Why?
Insurance, Health
1
2008
273
0.060
Why?
Risk Assessment
2
2016
3310
0.060
Why?
Fatty Acids, Omega-3
1
2006
139
0.060
Why?
Hyperglycemia
1
2009
326
0.060
Why?
Animals
3
2012
35076
0.060
Why?
Triglycerides
1
2006
525
0.060
Why?
Patient Compliance
1
2008
565
0.060
Why?
Enzyme Inhibitors
1
2007
832
0.050
Why?
Pandemics
2
2022
1538
0.050
Why?
Adolescent
4
2015
20374
0.050
Why?
Sleep
1
2008
673
0.050
Why?
Curriculum
1
2006
929
0.040
Why?
Lipids
1
2022
627
0.040
Why?
Annual Reports as Topic
1
2017
5
0.040
Why?
Students
1
2023
584
0.040
Why?
Pragmatic Clinical Trials as Topic
1
2017
62
0.040
Why?
Organizational Policy
1
2017
76
0.030
Why?
Randomized Controlled Trials as Topic
1
2021
1381
0.030
Why?
Health Personnel
1
2021
649
0.030
Why?
Eating
1
2016
368
0.030
Why?
Mechanical Thrombolysis
1
2013
5
0.030
Why?
Clinical Competence
2
2011
1029
0.030
Why?
Telephone
1
2013
169
0.020
Why?
Adrenergic Antagonists
1
2011
8
0.020
Why?
Thrombolytic Therapy
1
2013
137
0.020
Why?
Renin
1
2011
32
0.020
Why?
Angiotensin II Type 1 Receptor Blockers
1
2011
34
0.020
Why?
Phytotherapy
1
2011
76
0.020
Why?
Calcium Channel Blockers
1
2011
125
0.020
Why?
Drug Utilization
1
2011
170
0.020
Why?
Patient Care Management
1
2010
57
0.020
Why?
Cohort Studies
1
2020
5431
0.020
Why?
Hospitals, University
1
2010
177
0.020
Why?
Governing Board
1
2009
7
0.020
Why?
Prospective Studies
1
2020
7131
0.020
Why?
Length of Stay
1
2013
1135
0.020
Why?
Patient Readmission
1
2013
680
0.020
Why?
Databases, Factual
1
2013
1300
0.020
Why?
Inpatients
1
2010
462
0.020
Why?
Prevalence
1
2013
2576
0.020
Why?
Drug Combinations
1
2006
328
0.020
Why?
Primary Health Care
1
2015
1677
0.010
Why?
Marrs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)